BDTX (Black Diamond Therapeutics) Beta: 4.3775 (As of Jun. 26, 2026)


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Beta?

Black Diamond Therapeutics BDTX +0.59% 38 Beta is 4.3775 as of Jun. 26, 2026. GuruFocus rates BDTX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Black Diamond Therapeutics's Beta is 4.3775.


Black Diamond Therapeutics  (NAS:BDTX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Black Diamond Therapeutics Beta Related Terms


Black Diamond Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics Beta Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 1.54 3.43 3.59 5.83

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.67 4.88 5.08 5.83 4.64

BDTX vs GUTS, ALPS, ONCY: Beta Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Black Diamond Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Beta falls into.


BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 4.3775 mean?
Black Diamond Therapeutics (BDTX) has a Beta of 4.3775 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Black Diamond Therapeutics and its competitors.
Is Black Diamond Therapeutics' Beta too high?
Black Diamond Therapeutics' current Beta is 4.3775. Overall, Black Diamond Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' Beta compare to GUTS and ALPS?
Black Diamond Therapeutics' Beta of 4.3775 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current Beta is 4.3775. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current Beta of 4.3775. The current Beta is 4.3775. Black Diamond Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current Beta is 4.3775 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price